Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Feature
  • Published:

Biopharmaceutical benchmarks 2006

Nature Biotechnology volume 24, pages 769–776 (2006)Cite this article

The rate of biopharmaceutical approvals has leveled off, but some milestones bode well for the future.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2: Biopharmaceuticals in the pipeline.
Figure 3: Three-dimensional structure of human growth hormone.

References

  1. Lawrence, S. Biotech drug market steadily expands. Nat. Biotechnol. 23, 1466 (2005).

    Article  CAS  Google Scholar 

  2. Pavlou, A. & Belsey, M. The therapeutic antibody market to 2008. Eur. J. Pharm. Biopharm. 59, 389–396 (2005).

    Article  Google Scholar 

  3. Pavlou, A. & Reichert, J. Recombinant protein therapeutics—success rates, market trends and values to 2010. Nat. Biotechnol. 22, 1513–1519 (2004).

    Article  CAS  Google Scholar 

  4. Walsh, G. Biopharmaceutical benchmarks—2003. Nat. Biotechnol. 21, 865–870 (2003).

    Article  CAS  Google Scholar 

  5. World Health Organization. Diabetes Now http://www.idf.org/webdata/docs/diabetes_888k_version.pdf (2004).

  6. Kjeldsen, T. Yeast secretory expression of insulin precursors. Appl. Microbiol. Biotechnol. 54, 277–286 (2000).

    Article  CAS  Google Scholar 

  7. Walsh, G. Therapeutic insulins and their large-scale manufacture. Appl. Microbiol. Biotechnol. 67, 151–159 (2005).

    Article  CAS  Google Scholar 

  8. Brown, M., Martin, G., Jones, S. & Akomeah, F. Dermal and transdermal drug delivery systems: current and future prospects. Drug Deliv. 13, 175–187 (2006).

    Article  CAS  Google Scholar 

  9. Chen, Y. et al. Transdermal protein delivery by a coadministered peptide identified via phage display technology. Nat. Biotechnol. 24, 455–460 (2006).

    Article  CAS  Google Scholar 

  10. Hamman, J., Enslin, G.M. & Kotze, A.F. Oral delivery of peptide drugs—barriers and developments. BioDrugs 19, 165–177 (2005).

    Article  CAS  Google Scholar 

  11. Orive, G., Hernández, R.M., Rodríguez Gascón, A., Domínguez-Gil, A. & Pedraz, J.L. Drug delivery in biotechnology: present and future. Curr. Opin. Biotechnol. 14, 659–664 (2003).

    Article  CAS  Google Scholar 

  12. Upsher Smith Laboratories Inc. Fortical full prescribing information. http://www.upsher-smith.com/PDFs/forticalpi.pdf (2005).

  13. Patton, J.S., Bukar, J. & Nagarajan, S. Inhaled insulin. Adv. Drug Deliv. Rev. 35, 235–247 (1999).

    Article  CAS  Google Scholar 

  14. Pfizer/Aventis. Exubera European Public Assessment Report. http://www.emea.eu.int/humandocs/PDFs/EPAR/exubera/058806en1.pdf (2006).

  15. Wildt, S. & Gerngross, T. The humanization of N-glycosylation pathways in yeast. Nat. Rev. Microbiol. 3, 119–128 (2005).

    Article  CAS  Google Scholar 

  16. Gomord, W., Chamberlain, P., Jefferis, R. & Faye, L. Biopharmaceutical production in plants: problems, solutions and opportunities. Trends Biotechnol. 23, 559–565 (2005).

    Article  CAS  Google Scholar 

  17. Chen, M. et al. Modification of plant N-glycan processing: the future of producing therapeutic protein by transgenic plants. Med. Res. Rev. 25, 343–360 (2005).

    Article  CAS  Google Scholar 

  18. Gerngross, T.U. Advances in the production of human therapeutic proteins in yeasts and filamentous fungi. Nat. Biotechnol. 22, 1409–1414 (2004).

    Article  CAS  Google Scholar 

  19. Jarvis, D. Developing baculovirus-insect cell expression systems for humanized recombinant glycoprotein production. Virology 310, 1–7 (2003).

    Article  CAS  Google Scholar 

  20. Li, H. et al. Optimization of humanized IgGs in glycoengineered Pichia pastoris. Nat. Biotechnol. 24, 210–215 (2006).

    Article  CAS  Google Scholar 

  21. Werten, M.W., Van de Bosch, T.J., Wind, R.D., Mooibroek, H. & De Wolf, F.A. High-yield secretion of recombinant gelatins by Pichia pastoris. Yeast 15, 1087–1096 (1999).

    Article  CAS  Google Scholar 

  22. Butler, M. Animal cell cultures: recent achievements and perspectives in the production of biopharmaceuticals. Appl. Microbiol. Biotechnol. 68, 283–291 (2005).

    Article  CAS  Google Scholar 

  23. CHMP (2006) Press release: Questions and answers on recommendation for refusal of marketing application for ATRYN (Committee for Medicinal Products for Human Use, London, 2006).

  24. Ivarie, R. Competitive bioreactor hens on the horizon. Trends Biotechnol. 24, 99–101 (2006).

    Article  CAS  Google Scholar 

  25. Zhu, L. et al. Production of human monoclonal antibody in eggs of chimeric chickens. Nat. Biotechnol. 23, 1159–1169 (2005).

    Article  CAS  Google Scholar 

  26. Dyck, M. et al. Seminal vesicle production and secretion of growth hormone into seminal fluid. Nat. Biotechnol., 17, 1087–1090 (1999).

    Article  CAS  Google Scholar 

  27. Ben-Maimon, C. & Garnick, R. Biogenerics at the crossroads. Nat. Biotechnol. 24, 268–269 (2006).

    PubMed  Google Scholar 

  28. Diliberti, C. The best targets for biogenerics. BioPharm International 19, 50–64 (2006).

    CAS  Google Scholar 

  29. Fox, J. Sandoz sues FDA over delay in first biogeneric approval. Nat. Biotechnol. 23, 1327–1328 (2005).

    Article  CAS  Google Scholar 

  30. Peng, Z. The genesis of Gendicine. BioPharm International 17, 42–49 (2004).

    Google Scholar 

  31. Peng, Z. Current status of Gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. Hum. Gene Ther. 16, 1016–1027 (2005).

    Article  CAS  Google Scholar 

  32. Wilson, J. Gendicine: the first commercial gene therapy product. Hum. Gene Ther. 16, 1014 (2005).

    Article  CAS  Google Scholar 

  33. Verma, I. & Weitzman, M. Gene therapy: twenty first century medicine. Annu. Rev. Biochem. 74, 711–738 (2005).

    Article  CAS  Google Scholar 

  34. Vidal, L., Blagden, S., Attard, G. & deBono, J. Making sense of antisense. Eur. J. Cancer 41, 2812–2818 (2005).

    Article  CAS  Google Scholar 

  35. Khan, A. Ribozyme: a clinical tool. Clin. Chim. Acta 367, 20–27 (2006).

    Article  CAS  Google Scholar 

  36. Dallas, A. & Vlassov, A. RNAi: a novel antisense technology and its therapeutic potential. Med. Sci. Monit. 12, RA67–RA74 (2006).

    CAS  PubMed  Google Scholar 

  37. Jana S, Chakraborty C, Nandi S, Deb JK. RNA interference: potential therapeutic targets. Appl. Microbiol. Biotechnol. 65, 649–657 (2004).

    Article  CAS  Google Scholar 

  38. Jana, S., Chakraborty, C., Nandi, S. & Deb, J.K. RNA interference: potential therapeutic targets. Appl. Microbiol. Biotechnol. 65, 649–657 (2004).

    Article  CAS  Google Scholar 

  39. Zimmermann, T.S. et al. RNAi-mediated silencing in non-human primates. Nature 441, 111–114 (2006).

    Article  CAS  Google Scholar 

  40. Hermeling, S., Schellekens, H., Crommelin, D. & Jiskoot, W. Micelle-associated protein in Epoetin formulations: a risk factor for immunogenicity? Pharm. Res. 20, 1903–1907 (2003).

    Article  CAS  Google Scholar 

  41. Villalobos, A.P., Gunturi, S.R. & Heavner, G.A. Interaction of polysorbate 80 with erythropoietin: a case study in protein-surfactant interactions. Pharm. Res. 22, 1186–1194 (2005).

    Article  CAS  Google Scholar 

  42. Hermeling, S., Jiskoot, W., Crommelin, D. & Schellekens, H. Reaction to the paper: interaction of polysorbate 80 with erythropoietin: a case study in protein-surfactant interactions. Pharm. Res. 23, 641–642 (2006).

    Article  CAS  Google Scholar 

  43. Lim, L.C. Acquired red cell aplasia in association with the use of recombinant erythropoietin in chronic renal failure. Hematology (Am. Soc. Hematol. Educ. Program) 10, 255–259 (2005).

    CAS  Google Scholar 

  44. Sheridan, C. TeGenero fiasco prompts regulatory rethink. Nat. Biotechnol. 24, 475–476 (2006).

    Article  CAS  Google Scholar 

  45. Proske, D., Blank, M., Buhmann, R. & Resch, A. Aptamers—basic research, drug development, and clinical applications. Appl. Microbiol. Biotechnol. 69, 367–374 (2005).

    Article  CAS  Google Scholar 

  46. Nimjee, S.M., Rusconi, C.P. & Sullenger, B.A. Aptamers, an emerging class of therapeutics. Annu. Rev. Med., 56, 555–583 (2005).

    Article  CAS  Google Scholar 

  47. Hey, T., Fiedler, E., Rudolph, R. & Fiedler, M. Artificial, non-antibody binding proteins for pharmaceutical and industrial applications. Trends Biotechnol, 23, 514–522 (2005).

    Article  CAS  Google Scholar 

  48. Binz, H.K., Amstutz, P. & Pluckthun, A. Engineering novel binding proteins from nonimmunoglobulin domains. Nat. Biotechnol. 23, 1257–1268 (2005).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Industrial Biochemistry Programme, University of Limerick, Limerick, Ireland

    Gary Walsh

Authors
  1. Gary Walsh
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Walsh, G. Biopharmaceutical benchmarks 2006. Nat Biotechnol 24, 769–776 (2006). https://doi.org/10.1038/nbt0706-769

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0706-769

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing